EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers

Jumar Etkins iD, Gerald C So iD, Jessica Bo Li Lu, Sachiko Koyama iD, Debora L Gisch iD, Ricardo Melo Ferreira iD, Ying-Hua Cheng iD, Kelsey McClara, Joshua Jun, Matthew Miller iD, Zeruesenay Desta iD, Michael T Eadon iD

Clinical and Translational Science · 2026-01 · 19 (1)

DOI: 10.1111/cts.70455 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 26.12.2025. Verfasst von Jumar Etkins und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Cannabidiol. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCCIH NIH HHS, NIGMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cannabidiol (CBD) use has increased in America due to its widespread availability. Cannabidiol is metabolized by multiple polymorphic enzymes including CYP3A, CYP2C9, and CYP2C19. We sought to evaluate the genotype‐specific adverse events and pharmacokinetic profiles of cannabidiol, 7‐OH cannabidiol (an active metabolite), and 7‐COOH cannabidiol. We completed a secondary analysis of an open‐label, fixed‐sequence, single‐center study of cannabidiol in 33 healthy subjects. Patients first received a single dose of cannabidiol 5 mg/kg orally with serial plasma concentrations measured. Later, patients were titrated to 5 mg/kg twice daily for 14 days to reach steady state with serial plasma concentrations measured. CYP3A, CYP2C9, and CYP2C19 genotypes were assessed. Pharmacokinetic parameters were calculated by noncompartmental analysis. Diarrhea was observed more frequently in individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism (39%) compared to individuals with other genotypes (7%, p = 0.0463). Individuals with both CYP3A5 poor metabolism and CYP2C19 intermediate/normal metabolism had increased 7‐OH cannabidiol and 7‐COOH cannabidiol exposure at steady state. Cannabidiol parent drug exposure varied by CYP2C19 metabolizer status, with lower cannabidiol exposure and parent to metabolite ratios in intermediate metabolizers after single dose ( p = 0.014) and at steady state ( p = 0.0033). Similar CYP2C19 genotype‐specific exposure was observed in an external validation cohort. Minor differences in exposure of cannabidiol and its metabolites were observed between CYP3A5 and CYP2C9 genotype groups. Significant changes in pharmacokinetics were observed between CYP2C9, CYP2C19, and CYP3A5 genotype groups. Future studies should assess whether pharmacogenomics can predict intestinal concentrations of CBD, its metabolites, and diarrhea.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CannabidiolHumansMaleAdultFemaleHealthy VolunteersGenotypeMiddle AgedCytochrome P-450 CYP3ACytochrome P-450 CYP2C19Young AdultCytochrome P-450 CYP2C9Administration, OralAdolescent

Stichwörter der Autor:innen

7OH‐cannabidiolCYP2C19CYP2C9CYP3A4/5adverse drug eventdrug–drug interactionpharmacogenomics

Substanzen

CannabidiolCytochrome P-450 CYP3ACytochrome P-450 CYP2C19CYP2C19 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP2C9

Autor:innen und Institutionen

  • Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Division of Nephrology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

ORCID-Profile: Jumar Etkins, Gerald C So, Sachiko Koyama, Debora L Gisch, Ricardo Melo Ferreira, Ying-Hua Cheng, Matthew Miller, Zeruesenay Desta, Michael T Eadon

Förderung

  • NCCIH NIH HHS
  • NIGMS NIH HHS

Zitieren

APA

Etkins, J., So, G. C., Lu, J. B. L., Koyama, S., Gisch, D. L., Melo Ferreira, R., Cheng, Y. H., McClara, K., Jun, J., Miller, M., Desta, Z., & Eadon, M. T. (2026). Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. Clinical and Translational Science, 19(1). https://doi.org/10.1111/cts.70455

Vancouver

Etkins J, So GC, Lu JBL, Koyama S, Gisch DL, Melo Ferreira R, et al. Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers. Clinical and Translational Science. 2026;19(1). doi:10.1111/cts.70455

BibTeX
@article{Etkins2026,
  author = {Etkins, Jumar and So, Gerald C and Lu, Jessica Bo Li and Koyama, Sachiko and Gisch, Debora L and Melo Ferreira, Ricardo and Cheng, Ying-Hua and McClara, Kelsey and Jun, Joshua and Miller, Matthew and Desta, Zeruesenay and Eadon, Michael T},
  title = {Genotype–Specific Safety and Pharmacokinetics of Cannabidiol in Healthy Volunteers},
  journal = {Clinical and Translational Science},
  year = {2026},
  volume = {19},
  number = {1},
  doi = {10.1111/cts.70455}
}
Kostenlos starten →